Search for content, post, videos

Xbrane establishes new lab at Campus Solna

Xbrane team

In March 2021, Xbrane Biopharma will establish a new development lab for biosimilars with significantly expanded capacity compared to the current and will at the same time move its headquarter to Campus Solna.

From the second quarter of 2021 and onwards, Xbrane will further expand its portfolio and initiate development of additional biosimilar candidates on blockbuster biologics with patent expiration during this decade. Xbrane has expanded in recent years and advanced its biosimilar candidate Xlucane (Lucentis biosimilar) into phase III and entered into strategic partnerships with STADA, and Bausch + Lomb. In addition, Xbrane has three additional pre-clinical biosimilar candidates under development that address total originator sales of just under SEK 100 billion.  Furthermore, with Xlucane, Xbrane has validated its patented platform technology, which provides a significant cost advantage over competing systems and with another seven patent applications in 2020 worked actively with the IP protection of the platfor, it states.

“In order to fully leverage our platform technology and achieve our goal of becoming a leading global biosimilar developer, it is time for us to expand our capacity and broaden our portfolio. We have the technology and know-how and want to use it to develop more biosimilars on blockbuster biologics with patent expiration during this decade. The premises at Campus Solna suit us well for this purpose,” says Martin Åmark, CEO, Xbrane.

Part of a larger life science cluster

Xbrane will move its headquarter and establish a development lab with significantly expanded capacity and expect to, from second quarter 2021 and onwards, be able to start development of additional biosimilar candidates on blockbuster biologics with patent expiration during this decade.

This expansion includes the expansion of capacity where Xbrane develops the production processes for both mammalian cell- and E. coli-based biosimilars as well as the advanced analysis capacity needed during the development of biosimilars. Xbrane, together with other Swedish Life Science companies, will form part of a larger cluster at Campus Solna focusing on development and innovation in the Life Science sector.

Photo: Xbrane team